european_commission_web

EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits

pharmafile | May 21, 2018 | News story | Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta 

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the treatment of multiple sclerosis (MS), do not outweigh its risks, following a review carried out by the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) at the request of the European Commission.

The PRAC confirmed that the drug “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs”, and that “patients could be at risk from the start of treatment and for several months after stopping treatment, and it is not possible to predict which patients will be affected”.

The investigation followed 12 reports linking Zinbryta to cases of inflammatory brain disorders around the world such as encephalitis and meningoencephalitis, with three cases resulting in death. On 6 March, the PRAC recommended that the product be pulled from the European market, and by 27 March, Biogen and Abbvie voluntarily withdrew the drug from all markets.

Advertisement

Despite the fact that the review confirmed the PRAC’s original recommendation, there will be no immediate impact of the findings as Zinbryta is not currently authorised in the EU. The drug was first awarded approval in the region in 2016 for the treatment of relapsing forms of MS in adults.

Matt Fellows

Related Content

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content